In the ATTAIN obesity trials, maintenance doses of 6 mg, 12 mg, and 36 mg were evaluated, with 36 mg producing the greatest weight loss
Diarrhoea or Constipation : Digestive changes typically resolve within 4-8 weeks as your body adjusts
Thus we proposed the central idea of our commentary: Chronic glucagon suppression may shift amino-acid handling toward muscle proteolysis, creating a silent but progressive erosion of muscle reserve
Be cautious with: Crash diets and very low-calorie plans Aggressive fasting if you are not supervised Highly restrictive plans that cut major food groups without a medical reason If you have diabetes, kidney disease, or take insulin/sulfonylureas, get clinician input before big changes
Breakup by Region: North America United States Canada Europe Germany France United Kingdom Italy Spain Others Asia Pacific China Japan India South Korea Australia Indonesia Others Latin America Brazil Mexico Others Middle East and Africa North America leads the market, accounting for the largest GLP-1 receptor agonist market share The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada)
Weight loss and maintenance interventions involving nutritional advice and physical activity should be offered to individuals with type 1 diabetes who have overweight or obesity, in conjunction with other DSMES topics
